Ari Ne’eman, B.A., and David C. Grabowski, Ph.D.
doi : 10.1056/NEJMp2301998
Vol. 388 No. 20
Rupa Sheth Valdez, Ph.D., and Bonnielin K. Swenor, Ph.D., M.P.H.
doi : 10.1056/NEJMp2302561
Paul Sorajja, M.D., Brian Whisenant, M.D., Nadira Hamid, M.D., Hursh Naik, M.D., Raj Makkar, M.D., Peter Tadros, M.D., Matthew J. Price, M.D., Gagan Singh, M.D., Neil Fam, M.D., Saibal Kar, M.D., Jonathan G. Schwartz, M.D., Shamir Mehta, M.D.,
doi : 10.1056/NEJMoa2300525
Severe tricuspid regurgitation is a debilitating condition that is associated with substantial morbidity and often with poor quality of life. Decreasing tricuspid regurgitation may reduce symptoms and improve clinical outcomes in patients with this disease.
Le Wang, M.D., Ph.D., Hongsheng Wang, M.D., Ph.D., Liangbin Yan, M.D., Meiwen Yu, M.P.H., Jun Yang, M.D., Jinlan Li, M.P.H., Junhua Li, M.D., Yong Ning, M.D., Haiqin Jiang, Ph.D., Ying Shi, M.Sc., Wenyue Zhang, M.Sc., Li Xiong, M.D., Jie Liu, M.D., Yanfei Kuang, M.D., Hao Wang, M.D., Jun He, M.D., De Wang, M.D., Bin Li, M.D., Yangying Liu, M.D., Tiejun Shui, M.P.H., Ying Wang, M.D., Huan Chen, M.D., Xiaowei Sha, M.D., Heng Long, M.D., Xiaojin Yu, Ph.D., Chong Shen, Ph.D., Jianping Shen, M.D., Ph.D., Xueyuan Yang, M.D., Heng Gu, M.D., Ph.D., Guocheng Zhang, M.D., and Baoxi Wang, M.D., Ph.D.
doi : 10.1056/NEJMoa2205487
Previous studies have suggested that a single dose of rifampin has protective effects against leprosy in close contacts of patients with the disease. Rifapentine was shown to have greater bactericidal activity against Mycobacterium leprae than rifampin in murine models of leprosy, but data regarding its effectiveness in preventing leprosy are lacking.
Jay Tuttle, Ph.D., Edit Drescher, M.D., Jesus Abraham Simón-Campos, M.D., Paul Emery, M.D., Maria Greenwald, M.D., Alan Kivitz, M.D., Hyungmin Rha, Ph.D., Pia Yachi, M.D., Ph.D., Christina Kiley, Ph.D., and Ajay Nirula, M.D., Ph.D.
doi : 10.1056/NEJMoa2209856
Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a novel approach to the treatment of patients with autoimmune or autoinflammatory diseases.
Emmanuel C. Mrimi, M.Sc., Sophie Welsche, Ph.D., Said M. Ali, M.Sc., Jan Hattendorf, Ph.D., and Jennifer Keiser, Ph.D.
doi : 10.1056/NEJMoa2212825
Current treatments for soil-transmitted helminth infections in humans have low efficacy against Trichuris trichiura. Emodepside — a drug in veterinary use and under development for the treatment of onchocerciasis in humans — is a leading therapeutic candidate for soil-transmitted helminth infection.
Lei Wen, M.D., and Linbo Cai, M.D.
doi : 10.1056/NEJMicm2212333
William P. Schmitt, M.D., Saurabh Rohatgi, M.D., and Marcelo Matiello, M.D.
doi : 10.1056/NEJMcpc2300895
Mathias Orban, M.D., and Steffen Massberg, M.D.
doi : 10.1056/NEJMe2302457
David M. Scollard, M.D., Ph.D.
doi : 10.1056/NEJMe2302667
Ellen M. Gravallese, M.D., and Ranjeny Thomas, M.D.
doi : 10.1056/NEJMe2300734
Antonio Montresor, M.D., and Albis Francesco Gabrielli, M.D., Ph.D.
doi : 10.1056/NEJMe2303793
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟